QQQ   423.74 (-0.84%)
AAPL   181.39 (-0.09%)
MSFT   399.27 (-0.87%)
META   467.39 (-0.82%)
GOOGL   142.47 (+0.96%)
AMZN   168.39 (+0.78%)
TSLA   193.47 (-0.15%)
NVDA   671.21 (-3.36%)
NIO   6.05 (+1.51%)
AMD   163.59 (-1.27%)
BABA   75.69 (+3.49%)
T   16.96 (+0.30%)
F   12.10 (-1.22%)
MU   80.64 (-0.09%)
CGC   3.42 (-3.39%)
GE   148.32 (-0.20%)
DIS   107.78 (-1.52%)
AMC   4.54 (-2.58%)
PFE   27.45 (-0.51%)
PYPL   57.63 (-1.71%)
XOM   104.89 (+2.08%)
QQQ   423.74 (-0.84%)
AAPL   181.39 (-0.09%)
MSFT   399.27 (-0.87%)
META   467.39 (-0.82%)
GOOGL   142.47 (+0.96%)
AMZN   168.39 (+0.78%)
TSLA   193.47 (-0.15%)
NVDA   671.21 (-3.36%)
NIO   6.05 (+1.51%)
AMD   163.59 (-1.27%)
BABA   75.69 (+3.49%)
T   16.96 (+0.30%)
F   12.10 (-1.22%)
MU   80.64 (-0.09%)
CGC   3.42 (-3.39%)
GE   148.32 (-0.20%)
DIS   107.78 (-1.52%)
AMC   4.54 (-2.58%)
PFE   27.45 (-0.51%)
PYPL   57.63 (-1.71%)
XOM   104.89 (+2.08%)
QQQ   423.74 (-0.84%)
AAPL   181.39 (-0.09%)
MSFT   399.27 (-0.87%)
META   467.39 (-0.82%)
GOOGL   142.47 (+0.96%)
AMZN   168.39 (+0.78%)
TSLA   193.47 (-0.15%)
NVDA   671.21 (-3.36%)
NIO   6.05 (+1.51%)
AMD   163.59 (-1.27%)
BABA   75.69 (+3.49%)
T   16.96 (+0.30%)
F   12.10 (-1.22%)
MU   80.64 (-0.09%)
CGC   3.42 (-3.39%)
GE   148.32 (-0.20%)
DIS   107.78 (-1.52%)
AMC   4.54 (-2.58%)
PFE   27.45 (-0.51%)
PYPL   57.63 (-1.71%)
XOM   104.89 (+2.08%)
QQQ   423.74 (-0.84%)
AAPL   181.39 (-0.09%)
MSFT   399.27 (-0.87%)
META   467.39 (-0.82%)
GOOGL   142.47 (+0.96%)
AMZN   168.39 (+0.78%)
TSLA   193.47 (-0.15%)
NVDA   671.21 (-3.36%)
NIO   6.05 (+1.51%)
AMD   163.59 (-1.27%)
BABA   75.69 (+3.49%)
T   16.96 (+0.30%)
F   12.10 (-1.22%)
MU   80.64 (-0.09%)
CGC   3.42 (-3.39%)
GE   148.32 (-0.20%)
DIS   107.78 (-1.52%)
AMC   4.54 (-2.58%)
PFE   27.45 (-0.51%)
PYPL   57.63 (-1.71%)
XOM   104.89 (+2.08%)
LON:GSK

GSK (GSK) Share Price, News & Analysis

GBX 1,660.67
-17.13 (-1.02%)
(As of 04:35 PM ET)
Today's Range
1,655.40
1,666
50-Day Range
1,419.20
1,677.80
52-Week Range
1,302.60
1,685
Volume
4.38 million shs
Average Volume
7.31 million shs
Market Capitalization
£67.42 billion
P/E Ratio
1,383.89
Dividend Yield
3.85%
Price Target
GBX 1,668.89

GSK MarketRank™ Stock Analysis

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
0.5% Upside
GBX 1,668.89 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.56
Upright™ Environmental Score
News Sentiment
0.32mentions of GSK in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
£231.78 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.01 out of 5 stars


GSK stock logo

About GSK Stock (LON:GSK)

GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.

GSK Stock Price History

GSK Stock News Headlines

Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
GSK plc (LON:GSK) Insider Emma Walmsley Sells 139,792 Shares
Four Days Left Until GSK plc (LON:GSK) Trades Ex-Dividend
GSK Feb 2024 42.000 call
GSK (LON:GSK) Rating Reiterated by Shore Capital
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
GSK plc (LON:GSK) Insider Emma Walmsley Acquires 8 Shares
Citi changes its prescription for GSK
GSK India arm's Q3 profit falls on government price cap
GSK (LON:GSK) Rating Reiterated by Barclays
GSK Feb 2024 37.500 put
GSK settles another Zantac legal claim in California
See More Headlines
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/29/2020
Ex-Dividend for 1/11 Dividend
11/16/2023
Dividend Payable
1/11/2024
Today
2/21/2024
Ex-Dividend for 4/11 Dividend
2/22/2024
Dividend Payable
4/11/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
69,400
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 1,668.89
High Stock Price Target
GBX 2,000
Low Stock Price Target
GBX 1,300
Potential Upside/Downside
+0.7%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
£4.93 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£30.33 billion
Cash Flow
GBX 203.43 per share
Book Value
GBX 329 per share

Miscellaneous

Outstanding Shares
4,060,000,000
Free Float
N/A
Market Cap
£67.27 billion
Optionable
Not Optionable
Beta
0.26
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Ms. Emma Natasha Walmsley (Age 54)
    CEO & Director
    Comp: $4.79M
  • Ms. Julie Belita Brown (Age 62)
    CFO & Executive Director
  • Ms. Shobie Ramakrishnan
    Chief Digital & Technology Officer
  • Mr. Tony Wood
    Chief Scientific Officer
  • Ms. Sarah Elton-Farr
    Head of Investor Relations
  • Mr. James Ford
    Senior VP & Group General Counsel of Legal & Compliance
  • Ms. Sally Jackson
    Senior Vice President of Global Communications & CEO Office
  • Mr. David Simon Redfern BSc (Hons) (Age 58)
    CA, President of Corporate Development
  • Ms. Diana Conrad
    Chief People Officer
  • Mr. Philip C. Thomson
    President of Global Affairs

Should I Buy GSK Stock? GSK Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of GSK was last updated on Thursday, February 15, 2024 at 10:23 AM.

Pros

Here are some ways that investors could benefit from investing in GSK plc:

  • GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines and specialty medicines to prevent and treat various diseases. This positions the company in a crucial and high-demand sector, offering potential for long-term growth.
  • GSK plc has a strong track record of innovation and a robust pipeline of new products. This indicates the potential for future revenue growth and expansion into new markets.
  • The company has a global presence and operates in multiple countries. This diversification helps mitigate risks associated with regional economic fluctuations and regulatory changes.
  • GSK plc has a solid financial position, with a history of generating strong cash flows. This provides stability and the ability to invest in research and development, as well as pursue strategic acquisitions.
  • Recent developments indicate that GSK plc is actively investing in digital health technologies and partnerships. This positions the company at the forefront of healthcare innovation, which could lead to competitive advantages and improved patient outcomes.

Cons

Investors should be bearish about investing in GSK plc for these reasons:

  • GSK plc operates in a highly regulated industry, which exposes the company to risks associated with changing regulations, pricing pressures, and potential litigation.
  • The pharmaceutical industry is highly competitive, with numerous players vying for market share. This could impact GSK plc's ability to maintain or increase its market position.
  • There is a level of uncertainty surrounding the outcome of ongoing clinical trials and the success of new product launches. Failure to obtain regulatory approvals or achieve desired clinical outcomes could negatively impact the company's financial performance.
  • GSK plc has experienced management changes in recent years, which could introduce a level of uncertainty and impact the company's strategic direction.
  • The stock price of GSK plc is subject to market volatility and can be influenced by various factors, including macroeconomic conditions, industry trends, and investor sentiment.














GSK Stock Analysis - Frequently Asked Questions

Should I buy or sell GSK stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings
or view top-rated stocks.

What is GSK's stock price target for 2024?

7 brokerages have issued 12-month price targets for GSK's stock. Their GSK share price targets range from GBX 1,300 to GBX 2,000. On average, they expect the company's stock price to reach GBX 1,668.89 in the next twelve months. This suggests a possible upside of 0.5% from the stock's current price.
View analysts price targets for GSK
or view top-rated stocks among Wall Street analysts.

How have GSK shares performed in 2024?

GSK's stock was trading at GBX 1,450.20 at the beginning of the year. Since then, GSK stock has increased by 14.5% and is now trading at GBX 1,660.67.
View the best growth stocks for 2024 here
.

How were GSK's earnings last quarter?

GSK plc (LON:GSK) announced its quarterly earnings results on Wednesday, July, 29th. The company reported $56.90 earnings per share (EPS) for the quarter. GSK had a trailing twelve-month return on equity of 46.38% and a net margin of 16.25%.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK announced a dividend on Wednesday, January 31st. Shareholders of record on Thursday, February 22nd will be paid a dividend of GBX 16 per share on Thursday, April 11th. This represents a dividend yield of 1.04%. The ex-dividend date is Thursday, February 22nd. This is a boost from the stock's previous dividend of GBX 14. The official announcement can be accessed at this link.
Read our dividend analysis for GSK
.

Is GSK a good dividend stock?

GSK (LON:GSK) pays an annual dividend of GBX 64 per share and currently has a dividend yield of 3.82%. The dividend payout ratio is 5,333.33%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for GSK.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN), General Electric (GE), Royal Dutch Shell (RDSB), Vodafone Group Public (VOD), Intel (INTC), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Barclays (BARC) and Gilead Sciences (GILD).

How do I buy shares of GSK?

Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:GSK) was last updated on 2/21/2024 by MarketBeat.com Staff